Practical innovation, disciplined execution.
A disciplined development model built around reformulation opportunities, orphan pathways, targeted partnerships and regional licensing collaborations.
Four levers — applied programme-by-programme — to advance specialised products with retained long-term value.
Four levers, working together.
Our model combines reformulation, orphan pathways, targeted partnerships and regional licensing to advance specialised products with retained long-term value in key territories.
Each lever is selected on a programme-by-programme basis. The result is a pipeline that is commercially disciplined and clinically anchored — not optimised for one at the expense of the other.
Reformulation
We improve on existing products to address unmet metabolic patient needs and adoption barriers — refining tolerability, presentation and clinical fit so specialist teams can prescribe with confidence.
- Targeted reformulation of established products
- Optimised for paediatric and adult metabolic populations
- Designed to support existing dietary regimens
Orphan pathways
We pursue orphan designations in the FDA, EMA and MHRA to support development of programmes serving small, well-defined rare disease populations.
- Orphan designation strategy across major regulators
- Disciplined evidence generation for rare populations
- Engagement with patient and clinical communities
Regional licensing
We retain long-term value in key territories through structured licensing collaborations — extending access while keeping commercial control where it matters.
- Retained territorial value in core markets
- Selective licensing into specialist regional partners
- Aligned commercial and clinical incentives
Targeted partnerships
We work with regional specialists to extend access where local expertise — regulatory, clinical or distribution — is decisive to successful commercialisation.
- Co-development with specialist partners
- Region-specific regulatory and access expertise
- Coordinated launch and post-marketing support
From discovery to commercialisation.
Programmes are advanced through six clearly defined stages. Each stage has its own evidence requirements, milestones and commercial considerations.
- 01
Discovery
Early target and concept evaluation.
- 02
Formulation
Product and formulation development.
- 03
Preclinical
Preclinical evaluation and enabling studies.
- 04
Clinical
Clinical evaluation in patients.
- 05
Regulatory
Submission and regulatory review.
- 06
Commercial
Commercialised in one or more territories.
Explore the programmes being advanced through this approach.
The pipeline page is the most current view of our programmes — stage, geography, regulatory status and partner posture, all in one place.
Have a programme idea or partnership in mind?
